	US 11,692,025 B2
	Single domain binding molecule
Caroline Barelle, Aberdeen (GB); Mischa Roland Muller, Zurich-Schlieren (CH); Valerie Calabro, Carro (FR); Jack Bikker, Union Beach, NJ (US); John Steven, Aberdeen (GB); Lioudmila Tchistiakova, Cambridge, MA (US); Oleg Kovalenko, Cambridge, MA (US); and Andrea Olland, Arlington, MA (US)
Assigned to ELASMOGEN LIMITED, Aberdeen (GB)
Filed by ELASMOGEN LIMITED, Aberdeen (GB)
Filed on May 17, 2021, as Appl. No. 17/322,139.
Application 17/322,139 is a continuation of application No. 16/297,544, filed on Mar. 8, 2019, granted, now 11,034,756.
Application 16/297,544 is a continuation of application No. 15/273,197, filed on Sep. 22, 2016, granted, now 10,287,341, issued on May 14, 2019.
Application 15/273,197 is a continuation of application No. 15/005,463, filed on Jan. 25, 2016, granted, now 9,475,870, issued on Oct. 25, 2016.
Application 15/005,463 is a continuation of application No. 13/889,134, filed on May 7, 2013, abandoned.
Claims priority of provisional application 61/643,407, filed on May 7, 2012.
Prior Publication US 2021/0332116 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/18 (2013.01) [C07K 16/2827 (2013.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)]

34 Claims

1. A fusion protein comprising:

A) a single domain specific binding molecule comprising the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, in which:

i) FW1 comprises TRVDQSPSSLSASVGDRVTITCVLT (SEQ ID NO: 28), ARVDQSPSSLSASVGDRVTITCVLR (amino acids 1-25 of SEQ ID NO: 67) or TRVDQTPRTATRETGESLTINCVLT (SEQ ID NO: 1),

ii) FW2 comprises TYWYQQKPGS (SEQ ID NO: 29), TCWYQQKPGK (amino acids 34-43 of SEQ ID NO: 67), or TYWYRKNPGS (SEQ ID NO: 2),

iii) FW3a comprises GRYSESVN (SEQ ID NO: 30), or GRYVESVN (SEQ ID NO: 3),

iv) FW3b comprises FTLTISSLQPEDFATYYCRA (SEQ ID NO: 31), FTLTISSLQPEDFATYYCGL (amino acids 65-84 of SEQ ID NO: 67) or FSLRIKDLTVADSATYICRA (SEQ ID NO: 4), and

v) FW4 comprises GAGTKVEIK (SEQ ID NO: 32), CGQGTKVEIK (amino acids 103-112 of SEQ ID NO: 67) or GAGTVLTVN (SEQ ID NO: 5); or

B) a single domain specific binding molecule comprising framework regions FW1, FW2, FW3a, FW3b, and FW4 in which:

i) FW1 comprises a sequence having at least 50% identity to TRVDQSPSSLSASVGDRVTITCVLT (SEQ ID NO: 28), ARVDQSPSSLSASVGDRVTITCVLR (amino acids 1-25 of SEQ ID NO: 67) or TRVDQTPRTATRETGESLTINCVLT (SEQ ID NO: 1),

ii) FW2 comprises a sequence having at least 50% identity to TYWYQQKPGS (SEQ ID NO: 29), TCWYQQKPGK (amino acids 34-43 of SEQ ID NO: 67, or TYWYRKNPGS (SEQ ID NO: 2),

iii) FW3a comprises a sequence having at least 50% identity to GRYSESVN (SEQ ID NO: 30), or GRYVESVN (SEQ ID NO: 3),

iv) FW3b comprises a sequence having at least 50% identity to FTLTISSLQPEDFATYYCRA (SEQ ID NO: 31), FTLTISSLQPEDFATYYCGL (amino acids 65-84 of SEQ ID NO: 67) or FSLRIKDLTVADSATYICRA (SEQ ID NO: 4), and

v) FW4 comprises a sequence having at least 50% identity to GAGTKVEIK (SEQ ID NO: 32), CGQGTKVEIK (amino acids 103-112 of SEQ ID NO: 67) or GAGTVLTVN (SEQ ID NO: 5).